These and other outcomes for effectiveness of BTX-A at different dosages in two observation periods indicate that a dose greater than 50 U is significantly more effective for certain symptoms of OAB compared with placebo .
However , there were no significant differences between some dosages .
Compared with placebo , the outcomes of total adverse events for NDO and for IDO show that doses of 300 U and 200 U for NDO are associated with more complications .
Conclusions In consideration that the treatments of BTX-A were with minimal , local , and manageable adverse effects , this meta- analysis demonstrates that BTX-A 200 U is recommended for management of NDO for short-term treatment for there was no significant difference from the larger dose of 300U .
Purpose To assess the effectiveness and safety of botulinum toxin A ( BTX-A ) at different dosages for overactive bladder ( OAB ) .
Long-term efficacy and safety of onabotulinumtoxinA in patients with urinary incontinence due to neurogenic detrusor overactivity: an interim analysis.
OBJECTIVE To evaluate the long-term efficacy and safety of repeat onabotulinumtoxinA injections in patients inadequately managed by anticholinergics for urinary incontinence ( UI ) due to neurogenic detrusor overactivity . MATERIAL S AND METHODS Patients who completed either of 2 preceding phase III studies were offered entry into an extension study and received repeat onabotulinumtoxinA 200 U or 300 U. The data were integrated across the phase III and ongoing extension studies . The present interim analysis included all patients who received ≥ 1 onabotulinumtoxinA treatment . The data were analyzed by treatment cycle ( cycles 1 - 5 ) . The primary assessment was the change from baseline in UI episodes/wk at 6 weeks after each treatment . Additional assessment s included ≥ 50 % and 100 % reductions in UI episodes , volume/void , Incontinence Quality of Life responses , and adverse events . RESULTS A total of 387 , 336 , 241 , 113 , and 46 patients received 1 , 2 , 3 , 4 , and 5 onabotulinumtoxinA treatments , respectively . The UI episodes/wk were consistently reduced compared with baseline after repeated onabotulinumtoxinA treatment ( -22.7 , -23.3 , -23.1 , -25.3 , and -31.9 for the 200-U onabotulinumtoxinA group in cycles 1 - 5 ) . The proportion of patients reporting ≥ 50 % and 100 % ( " dry " ) reductions from baseline in UI episodes at week 6 ranged from 73%-94 % and 36%-55 % , respectively . Increases in the mean volume/void ( mean increase > 130 mL ) and improvements in quality of life were also observed after repeat treatment . The most common adverse events were urinary tract infections and urinary retention , with no change in the adverse event profile over time . CONCLUSION The results of our study have shown that repeated onabotulinumtoxinA treatments provide sustained reductions in UI episodes and increases in the volume/void and quality of life in patients with neurogenic detrusor overactivity and UI who were inadequately managed by anticholinergics , with no new safety signals
These and other outcomes for effectiveness of BTX-A at different dosages in two observation periods indicate that a dose greater than 50 U is significantly more effective for certain symptoms of OAB compared with placebo .
However , there were no significant differences between some dosages .
Compared with placebo , the outcomes of total adverse events for NDO and for IDO show that doses of 300 U and 200 U for NDO are associated with more complications .
Conclusions In consideration that the treatments of BTX-A were with minimal , local , and manageable adverse effects , this meta- analysis demonstrates that BTX-A 200 U is recommended for management of NDO for short-term treatment for there was no significant difference from the larger dose of 300U .
Purpose To assess the effectiveness and safety of botulinum toxin A ( BTX-A ) at different dosages for overactive bladder ( OAB ) .